What does ohtuvayre — total revenues and income mean?

This metric represents the aggregate financial inflows generated by the Ohtuvayre product line, including royalties, milestone payments, and licensing fees. It serves as a key indicator of the commercial adoption and market performance of this specific therapeutic asset within the company's portfolio. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the asset independent of the broader corporate results.

Ligand Pharmaceuticals (LGND) Ohtuvayre — Total revenues and income

Screener

Other product segments

Filspari

$13.57M+106%

Captisol

$7.98M—

Kyprolis

$7.04M—

Qarziba

$6.15M+4.5%

Evomela

$5.94M-31.5%

Rylaze

$3.81M+3.7%

Ohtuvayre inventors

$3.29M—

Contract revenue

$2.68M—

Other

$2.59M—

Capvaxive

$2.32M—

Teriparatide injection

$2.03M+19.2%

Vaxneuvance

$1.35M-48.9%

Similar metrics at other companies

PTH

PTHSLicense and collaboration revenues — Total Revenue

$241K—

QTRXCollaboration and license revenue — Total revenues

$560K-27.4%

QTRXService and other revenue — Total revenues

$10.38M+17.6%

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ESP

ESPRCollaboration revenue — Total Revenues

$36.71M+22.0%

Other financials

Income statement

See full

Revenue$63.7M+33.7%

Operating income$8.6M+1.7%

Net income$48.5M+901%

EPS (diluted)$2.22+825%

Balance sheet

See full

Cash & equivalents$1.0B+1,388%

Total debt$1.1B+19,605%

Total equity$967.5M+16.9%

Total assets$2.2B+130%

Cash flow

See full

Operating cash flow$24.0M+52.0%

CapEx$26.0K-87.9%

Free cash flow$24.0M+53.9%

Valuation

See full

Market cap$6.02B+119%

Enterprise value$6.14B+129%

P/E30.5×—

P/S20.7×+6.1×

Profitability

See full

Gross margin91.9%—

Operating margin32.6%+24.0pp

Net margin67.9%+49.4pp

FCF margin45.2%+16.7pp

Returns & leverage

See full

Return on equity22%+16.9pp

Debt / equity1.2×+1.2×

Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 4:06 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000886163-26-000044

Line item	Three months ended / June 30, 2026	Three months ended / June 30, 2025	Six months ended / June 30, 2026	Six months ended / June 30, 2025
Royalties
Filspari	$13,567	$6,578	$24,889	$11,879
Kyprolis	7,044	8,803	13,784	13,526
Ohtuvayre	4,144	2,084	7,131	3,496
Rylaze	3,201	2,864	6,422	5,983
Capvaxive	2,316	2,250	4,285	3,135
Vaxneuvance	1,351	2,643	2,961	3,928
Teriparatide injection	1,470	2,298	2,791	3,489

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's ohtuvayre — total revenues and income?: Ligand Pharmaceuticals (LGND) reported ohtuvayre — total revenues and income of $4.14M in Q2 2026.
What does ohtuvayre — total revenues and income mean?: This metric represents the aggregate financial inflows generated by the Ohtuvayre product line, including royalties, milestone payments, and licensing fees. It serves as a key indicator of the commercial adoption and market performance of this specific therapeutic asset within the company's portfolio. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the asset independent of the broader corporate results.